Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer


Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and
Actual Patients with Non-Small Cell Lung Cancer
Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Matthew D Hellmann, Corey J Langer, Geoffrey R Oxnard, Martin Reck and Alice Shaw.
2.5 AMA PRA Category 1 Credits™
To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CME credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Introduction

Long-Term Management of Non-Small Cell Lung Cancer (NSCLC) in Patients with an Activating EGFR Mutation

Recent Treatment Advances for Patients with ALK/ROS1- and BRAF-Positive NSCLC; Other Targets with the Potential to Affect Treatment Decision-Making

Optimal Integration of Immune Checkpoint Inhibition into Clinical Decision-Making for Patients with Locally Advanced NSCLC

Current Role of Immune Checkpoint Inhibitors in Combination with Chemotherapy and/or Anti-angiogenic Agents in the Treatment of Metastatic Disease

  • Potential Role of Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies in Combination; Future Directions for Clinical Research